AIMS: Methadone maintenance has been an effective pharmacotherapy for the treatment of heroin dependence for nearly four decades. Recent clinical research suggests that methadone doses larger than those used in most clinics are more effective at suppressing illicit heroin use. This greater efficacy may result from greater cross-tolerance to the reinforcing effects of heroin. DESIGN: The purpose of this double-blind, within-subject study was to examine the relationship between methadone maintenance dose and the reinforcing effects of heroin. SETTING: Participants were stabilized on 50, 100 and 150 mg methadone (ascending order) during separate outpatient periods before being admitted to an inpatient research unit for testing at each maintenance dose. PARTICIPANTS: Five opiate-dependent volunteers completed the study. MEASUREMENTS: During each 4-week inpatient testing period, participants sampled three doses of heroin (0, 10, or 20 mg; random order; one dose per week) and were subsequently allowed seven opportunities to choose between another injection of that week's heroin dose and varying amounts of money (dollars 2-38). FINDINGS: The number of heroin injections chosen decreased as methadone dose was increased. Larger alternative monetary reinforcers were required to suppress heroin self-administration during maintenance on 50 compared to 100 or 150 mg methadone. Larger methadone doses also completely blocked the subjective effects of heroin and produced greater withdrawal suppression during the outpatient periods. CONCLUSIONS: These results support other clinical and laboratory-based research indicating that persistent heroin use may be reduced by providing larger methadone maintenance doses that produce more effective cross-tolerance to heroin.
RCT Entities:
AIMS: Methadone maintenance has been an effective pharmacotherapy for the treatment of heroin dependence for nearly four decades. Recent clinical research suggests that methadone doses larger than those used in most clinics are more effective at suppressing illicit heroin use. This greater efficacy may result from greater cross-tolerance to the reinforcing effects of heroin. DESIGN: The purpose of this double-blind, within-subject study was to examine the relationship between methadone maintenance dose and the reinforcing effects of heroin. SETTING:Participants were stabilized on 50, 100 and 150 mg methadone (ascending order) during separate outpatient periods before being admitted to an inpatient research unit for testing at each maintenance dose. PARTICIPANTS: Five opiate-dependent volunteers completed the study. MEASUREMENTS: During each 4-week inpatient testing period, participants sampled three doses of heroin (0, 10, or 20 mg; random order; one dose per week) and were subsequently allowed seven opportunities to choose between another injection of that week's heroin dose and varying amounts of money (dollars 2-38). FINDINGS: The number of heroin injections chosen decreased as methadone dose was increased. Larger alternative monetary reinforcers were required to suppress heroin self-administration during maintenance on 50 compared to 100 or 150 mg methadone. Larger methadone doses also completely blocked the subjective effects of heroin and produced greater withdrawal suppression during the outpatient periods. CONCLUSIONS: These results support other clinical and laboratory-based research indicating that persistent heroin use may be reduced by providing larger methadone maintenance doses that produce more effective cross-tolerance to heroin.
Authors: Sandra D Comer; Warren K Bickel; Richard Yi; Harriet de Wit; Stephen T Higgins; Galen R Wenger; Chris-Ellyn Johanson; Mary Jeanne Kreek Journal: Behav Pharmacol Date: 2010-07 Impact factor: 2.293
Authors: Barrot H Lambdin; Frank Masao; Olivia Chang; Pamela Kaduri; Jessie Mbwambo; Ayoub Magimba; Norman Sabuni; R Douglas Bruce Journal: Clin Infect Dis Date: 2014-05-22 Impact factor: 9.079
Authors: Shadi Nahvi; Alain H Litwin; Moonseong Heo; Karina M Berg; Xuan Li; Julia H Arnsten Journal: Drug Alcohol Depend Date: 2011-08-31 Impact factor: 4.492
Authors: Takato Hiranita; Stephen J Kohut; Paul L Soto; Gianluigi Tanda; Theresa A Kopajtic; Jonathan L Katz Journal: J Pharmacol Exp Ther Date: 2013-11-05 Impact factor: 4.030